FDA wants to remove cholesterol drug from market
The U.S. Food and Drug Administration (FDA) wants to withdraw its approval of a prescription statin after the manufacturer repeatedly failed to file reports at the agency’s request. This would effectively cause the drug to be pulled from store shelves throughout the United States.
The drug in question, simvastatin, is a liquid statin sold by Oklahoma-based Salerno Pharmaceuticals under the brand name FloLipid. The FDA first approved the company’s simvastatin formulation back in 2016.
The FDA’s proposal covers 20-mg and 40-mg doses of this liquid statin, which Salerno Pharmaceuticals markets as the “first cholesterol medication in liquid form to be provided to U.S. patients.” It was developed to provide an alternative cholesterol therapy for patients who find it difficult to swallow pills and does not require refrigeration.
According to details available from the Federal Registrar, Salerno Pharmaceuticals has until Dec. 18 to request a hearing. The company then has until Jan. 19, 2027, to submit all relevant data, including any written comments.
Additional details about the FDA notice
Companies are required to submit annual reports after securing approval for a new drug application (NDA). However, according to the FDA, Salerno Pharmaceuticals has failed to submit those reports on multiple occasions and even failed to respond to the agency’s requests. If the company now fails to request a hearing in time, that “constitutes a waiver of any contentions concerning the legal status of the drug products.”
“FDA will then withdraw approval of the NDA, and the drug products may not thereafter be lawfully introduced or delivered for introduction into interstate commerce,” according to the proposal. “Any new drug product introduced or delivered for introduction into interstate commerce without an approved NDA is subject to regulatory action at any time.”
Michael Davis, MD, PhD, director of the FDA’s Center for Drug Evaluation and Research, signed the notice.

